Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

7Total
Not Applicable (1)
P 1 (4)
P 2 (2)

Trial Status

Active Not Recruiting3
Withdrawn2
Recruiting1
Terminated1

Clinical Trials (7)

Showing 7 of 7 trials
NCT03435952Phase 1Active Not Recruiting

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

NCT03114501Not ApplicableActive Not RecruitingPrimary

Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers

NCT03224000Phase 2Active Not RecruitingPrimary

Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

NCT03093909Phase 1Recruiting

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

NCT03258008Phase 2Terminated

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

NCT02915172Phase 1Withdrawn

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

NCT02812056Phase 1Withdrawn

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Showing all 7 trials

Research Network

Activity Timeline